Table 4.
Basic information matching analysis.
| CD4+CD45RA− T cell | P-value | CD8+ T/lymphocyte (%) | P-value | |||
|---|---|---|---|---|---|---|
| Low | High | Low | High | |||
| Patients | 68 | 68 | 68 | 68 | ||
| Sex | 1.000 | 0.710 | ||||
| Male | 47 (69.1%) | 47 (69.1%) | 46 (67.6%) | 48 (70.6%) | ||
| Female | 21 (30.9%) | 21 (30.9%) | 22 (32.4%) | 20 (29.4%) | ||
| Age | 0.424 | 0.161 | ||||
| <60 | 14 (20.6%) | 19 (27.9%) | 20 (29.4%) | 13 (19.1%) | ||
| ≥60 | 54 (79.4%) | 49 (72.1%) | 48 (70.6%) | 55 (80.9%) | ||
| Histology | 0.168 | 0.605 | ||||
| Non-squamous carcinoma | 42 (61.8%) | 33 (48.5%) | 39 (57.4%) | 36 (52.9%) | ||
| Squamous carcinoma | 26 (38.2%) | 35 (51.5%) | 29 (42.6%) | 32 (47.1%) | ||
| Line of therapy | 0.003 | 0.765 | ||||
| First line | 30 (44.1%) | 49 (72.1%) | 38 (55.9%) | 41 (60.3%) | ||
| Second line | 30 (44.1%) | 17 (25.0%) | 24 (35.3%) | 23 (33.8%) | ||
| Third line and beyond | 8 (11.8%) | 2 (2.9%) | 6 (8.8%) | 4 (5.9%) | ||
| Combined chemotherapy | 0.419 | 1.000 | ||||
| No | 18 (26.5%) | 14 (20.6%) | 16 (23.5%) | 16 (23.5%) | ||
| Yes | 50 (73.5%) | 54 (79.4%) | 52 (76.5%) | 52 (76.5%) | ||
| Smoking status | 0.217 | 0.158 | ||||
| No | 30 (44.1%) | 22 (32.4%) | 30 (44.1%) | 22 (32.4%) | ||
| Yes | 38 (55.9%) | 46 (67.6%) | 38 (55.9%) | 46 (67.6%) | ||
| Drinking status | 0.572 | 0.707 | ||||
| No | 50 (73.5%) | 46 (67.6%) | 49 (72.1%) | 47 (69.1%) | ||
| Yes | 18 (26.5%) | 22 (32.4%) | 19 (27.9%) | 21 (30.9%) | ||
| ECOG PS | 0.625 | 0.293 | ||||
| 0 | 33 (48.5%) | 37 (54.5%) | 38 (55.9%) | 32 (47.1%) | ||
| 1 | 27 (39.7%) | 26 (38.2%) | 26 (38.2%) | 27 (39.7%) | ||
| 2–4 | 8 (11.8%) | 5 (7.4%) | 4 (5.9%) | 9 (13.2%) | ||